Download PDF
Horm Metab Res 2012; 44(03): 239-244
DOI: 10.1055/s-0031-1295459
Original Basic
© Georg Thieme Verlag KG Stuttgart · New York

Diabetic Lipoproteins and Adrenal Aldosterone Synthesis – A Possible Pathophysiological Link?

S. Saha
1   Department of Internal Medicine 3, Carl Gustav Carus Medical School, Technical University of Dresden, Dresden, Germany
,
H. S. Willenberg
2   Department of Endocrinology, Diabetes and Rheumatology, University Hospital Düsseldorf, Düsseldorf, Germany
,
S. R. Bornstein
1   Department of Internal Medicine 3, Carl Gustav Carus Medical School, Technical University of Dresden, Dresden, Germany
,
J. Graessler
1   Department of Internal Medicine 3, Carl Gustav Carus Medical School, Technical University of Dresden, Dresden, Germany
,
S. Kopprasch
1   Department of Internal Medicine 3, Carl Gustav Carus Medical School, Technical University of Dresden, Dresden, Germany
› Author Affiliations
Further Information

Publication History

received 29 August 2011

accepted 27 October 2011

Publication Date:
06 December 2011 (online)

Also available at
    Permissions and Reprints

Abstract

An increased prevalence of diabetes mellitus (DM) has been reported in patients with primary aldosteronism (PA). DM is associated with abnormal structure and metabolism of circulating lipoproteins, which normally serve as a major source of cholesterol for adrenocortical steroidogenesis. The present study has been designed to investigate the effect of diabetically modified lipoproteins on adrenocortical aldosterone synthesis. Lipoproteins (VLDL, LDL, HDL) isolated from healthy volunteers, were subjected to oxidation or glycoxidation in the presence of sodium hypochlorite (3 mmol/l) or glucose (200 mmol/l), and aldosterone synthesis in human adrenocortical cells (H295R) was examined. Native and glycoxidized VLDL had greatest stimulatory effect on aldosterone production by 15-fold and 14-fold, respectively. At the molecular level, these VLDL produced maximum increases in Cyp11B2 mRNA level up to 17-fold. Experiments with the highly selective scavenger receptor class B type I (SR-BI) inhibitor BLT-1 revealed that cholesterol uptake from native and glycoxidized HDL and VLDL for hormone production is considerably mediated by SR-BI. Western blot analysis of extracellular signal-regulated kinase (ERK 1/2) phosphorylation and experiments with the MEK inhibitor U0126 indicated a specific mechanistic role of the ERK cascade in lipoprotein-mediated steroid hormone release. In summary, diabetic dyslipidemia and modification of circulating lipoproteins may promote adrenocortical aldosterone synthesis.

Key words

glycoxidation - oxidation - adrenocortical cells - scavenger receptor - extracellular signal-regulated kinase
 

  • References

  • 1 Matrozova J, Steichen O, Amar L, Zacharieva S, Jeunemaitre X, Plouin PF. Fasting plasma glucose and serum lipids in patients with primary aldosteronism: a controlled cross-sectional study. Hypertension 2009; 53: 605-610
    Google Scholar
  • 2 Catena C, Lapenna R, Baroselli S, Nadalini E, Colussi G, Novello M, Favret G, Melis A, Cavarape A, Sechi LA. Insulin sensitivity in patients with primary aldosteronism: a follow-up study. J Clin Endocrinol Metab 2006; 91: 3457-3463
    Google Scholar
  • 3 Mosso LM, Carvajal CA, Maiz A, Ortiz EH, Castillo CR, Artigas RA, Fardella CE. A possible association between primary aldosteronism and a lower beta-cell function. J Hypertens 2007; 25: 2125-2130
    Google Scholar
  • 4 Fallo F, Veglio F, Bertello C, Sonino N, Della Mea P, Ermani M, Rabbia F, Federspil G, Mulatero P. Prevalence and characteristics of the metabolic syndrome in primary aldosteronism. J Clin Endocrinol Metab 2006; 91: 454-459
    Google Scholar
  • 5 Reincke M, Meisinger C, Holle R, Quinkler M, Hahner S, Beuschlein F, Bidlingmaier M, Seissler J, Endres S. Is primary aldosteronism associated with diabetes mellitus? Results of the German Conn’s Registry. Horm Metab Res 2010; 42: 435-439
    Google Scholar
  • 6 Wada T, Ohshima S, Fujisawa E, Koya D, Tsuneki H, Sasaoka T. Aldosterone inhibits insulin-induced glucose uptake by degradation of insulin receptor substrate (IRS) 1 and IRS2 via a reactive oxygen species-mediated pathway in 3T3-L1 adipocytes. Endocrinology 2009; 150: 1662-1669
    Google Scholar
  • 7 Hitomi H, Kiyomoto H, Nishiyama A, Hara T, Moriwaki K, Kaifu K, Ihara G, Fujita Y, Ugawa T, Kohno M. Aldosterone suppresses insulin signaling via the downregulation of insulin receptor substrate-1 in vascular smooth muscle cells. Hypertension 2007; 50: 750-755
    Google Scholar
  • 8 Yamashita R, Kikuchi T, Mori Y, Aoki K, Kaburagi Y, Yasuda K, Sekihara H. Aldosterone stimulates gene expression of hepatic gluconeogenic enzymes through the glucocorticoid receptor in a manner independent of the protein kinase B cascade. Endocr J 2004; 51: 243-251
    CrossrefPubMedGoogle Scholar
  • 9 Laverty G, Bjarnadottir S, Elbrond VS, Arnason SS. Aldosterone suppresses expression of an avian colonic sodium-glucose cotransporter. Am J Physiol Regul Integr Comp Physiol 2001; 281: R1041-R1050
    PubMedGoogle Scholar
  • 10 Krug AW, Ehrhart-Bornstein M. Aldosterone and metabolic syndrome: is increased aldosterone in metabolic syndrome patients an additional risk factor?. Hypertension 2008; 51: 1252-1258
    CrossrefPubMedGoogle Scholar
  • 11 Sowers JR, Whaley-Connell A, Epstein M. Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension. Ann Intern Med 2009; 150: 776-783
    CrossrefPubMedGoogle Scholar
  • 12 Azhar S, Leers-Sucheta S, Reaven E. Cholesterol uptake in adrenal and gonadal tissues: the SR-BI and ‘selective’ pathway connection. Front Biosci 2003; 8: s998-s1029
    CrossrefPubMedGoogle Scholar
  • 13 Maeba R, Shimasaki H, Ueta N. Conformational changes in oxidized LDL recognized by mouse peritoneal macrophages. Biochim Biophys Acta 1994; 1215: 79-86
    CrossrefPubMedGoogle Scholar
  • 14 Levine RL, Garland D, Oliver CN, Amici A, Climent I, Lenz AG, Ahn BW, Shaltiel S, Stadtman ER. Determination of carbonyl content in oxidatively modified proteins. Methods Enzymol 1990; 186: 464-478
    PubMedGoogle Scholar
  • 15 Yagi K. A simple fluorometric assay for lipoperoxide in blood plasma. Biochem Med 1976; 15: 212-216
    CrossrefPubMedGoogle Scholar
  • 16 Quinkler M, Born-Frontsberg E, Fourkiotis VG. Comorbidities in primary aldosteronism. Horm Metab Res 2010; 42: 429-434
    Google Scholar
  • 17 Giacchetti G, Sechi LA, Rilli S, Carey RM. The renin-angiotensin-aldosterone system, glucose metabolism and diabetes. Trends Endocrinol Metab 2005; 16: 120-126
    CrossrefPubMedGoogle Scholar
  • 18 Howard BV. Lipoprotein metabolism in diabetes mellitus. J Lipid Res 1987; 28: 613-628
    PubMedGoogle Scholar
  • 19 Xing Y, Cohen A, Rothblat G, Sankaranarayanan S, Weibel G, Royer L, Francone OL, Rainey WE. Aldosterone production in human adrenocortical cells is stimulated by high-density lipoprotein 2 (HDL2) through increased expression of aldosterone synthase (CYP11B2). Endocrinology 2011; 152: 751-763
    CrossrefPubMedGoogle Scholar
  • 20 Nieland TJ, Chroni A, Fitzgerald ML, Maliga Z, Zannis VI, Kirchhausen T, Krieger M. Cross-inhibition of SR-BI- and ABCA1-mediated cholesterol transport by the small molecules BLT-4 and glyburide. J Lipid Res 2004; 45: 1256-1265
    CrossrefPubMedGoogle Scholar
  • 21 Fardella CE, Mosso L, Gomez-Sanchez C, Cortes P, Soto J, Gomez L, Pinto M, Huete A, Oestreicher E, Foradori A, Montero J. Primary hyperaldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology. J Clin Endocrinol Metab 2000; 85: 1863-1867
    CrossrefPubMedGoogle Scholar
  • 22 Gomez-Sanchez CE, Rossi GP, Fallo F, Mannelli M. Progress in primary aldosteronism: present challenges and perspectives. Horm Metab Res 2010; 42: 374-381
    Article in Thieme ConnectPubMedGoogle Scholar